COMMUNIQUÉS West-GlobeNewswire

Adia Nutrition Officially Enters $15.1 Billion Global Stem Cell Market with Domestic Treatments by Successful Opening of First Florida Location
03/02/2025
WINTER PARK, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Adia Nutrition Inc. (OTC Pink: ADIA), through its medical division Adia Med, is strategically positioning itself to capture a significant share of the growing $15.1 [...]
MedBright AI Appointments Brandon Kou as Director
03/02/2025
VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the “ Company ” or “ MedBright AI ”) (CSE:MBAI, OTCQB:MBAIF, FSE:Y30) is pleased to announce that Brandon Kou has joined [...]
Safety Shot, Inc. Terminates At-the-Market Equity Offering, Reaffirms Strong Financial Position and Growth Trajectory
03/02/2025
SCOTTSDALE, Ariz., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) ("Safety Shot" or the "Company"), a leading wellness and dietary supplement company, today announced the termination of its at-the- [...]
Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation
03/02/2025
Dallas, TX & Quebec, Canada, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of men’s wellness products and services via a [...]
Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study
03/02/2025
HOUSTON, TX, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announces the [...]
Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine
03/02/2025
Funding will Support Ongoing RIDGE™ -1 Clinical Trial of TN-401 Gene Therapy for the Potential Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Initial Data from RIDGE-1 Phase 1b Clinical [...]
Annovis Bio, Inc. Announces Proposed Public Offering
01/02/2025
MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for [...]
Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
31/01/2025
IRVINE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the closing of its upsized initial [...]
The Ensign Group Schedules Year End 2024 Earnings Call for Thursday, February 6, 2025
31/01/2025
SAN JUAN CAPISTRANO, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
Evaxion announces closing of $10.8 million public offering
31/01/2025
COPENHAGEN, Denmark, January 31, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing of a [...]
GH Research to Provide Update on Phase 2b Trial with GH001 in TRD
31/01/2025
DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced [...]
Oculis updates share capital for its existing at-the-market offering program
31/01/2025
ZUG, Switzerland, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each [...]
Bavarian Nordic – Completion of Share Buy-Back Program
31/01/2025
COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 9, 2025, has now been completed, reaching an aggregate [...]
Women in Science: Breaking Barriers with HNL Lab Medicine
31/01/2025
ALLENTOWN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Women are still vastly underrepresented in science, technology, engineering, and math (STEM) fields, with only 18% of women holding STEM jobs in the United States, [...]
EssilorLuxottica: Full-Year 2024 Results Conference Call Invitation
31/01/2025
Full-Year 2024 Results Conference Call Invitation Mr FRANCESCO MILLERI, Chairman and Chief Executive Officer, Mr PAUL DU SAILLANT, Deputy Chief Executive Officer, Mr STEFANO GRASSI, Chief Financial Officer, and Mr [...]
EssilorLuxottica: Full-Year 2024 Results Conference Call Invitation
31/01/2025
Full-Year 2024 Results Conference Call Invitation Mr FRANCESCO MILLERI, Chairman and Chief Executive Officer, Mr PAUL DU SAILLANT, Deputy Chief Executive Officer, Mr STEFANO GRASSI, Chief Financial Officer, and Mr [...]
Aclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine Conference
31/01/2025
Dr. Sigurd Berven to Highlight NOCISCAN Capabilities, Combining MR Spectroscopy and Augmented Intelligence (AI) NOCISCAN as New Gold Standard in Identifying a Source of Discogenic Pain BROOMFIELD, Colo., Jan. 31, 2025 ( [...]
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
31/01/2025
As seen in the DESTINY-Breast06 trial, a pproximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow. 1 These patients may now be eligible for a [...]
Correction: GUERBET : Financial agenda for 2025
31/01/2025
CORRECTION - Financial agenda for 2025 Villepinte, 13 janvier 2025 : Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2025. [...]

Pages